Apotex further expands oncology franchise by acquiring Canadian rights to toripalimab

Toripalimab Becomes Apotex’s First Innovative Biologic Drug

TORONTO, July 2, 2024 /CNW/ – Apotex Inc. (“Apotex”), Canada’s largest pharmaceutical company, today announced an exclusive agreement with Coherus Biosciences, Inc. (“Coherus”) to license the Canadian rights to toripalimab, an anti-PD-1 monoclonal antibody, under which Apotex will commercialize and distribute toripalimab in Canada upon approval. The agreement further expands Apotex’s oncology franchise, with toripalimab becoming the first novel biologic medicine in Apotex’s portfolio.

“With this licensing agreement with Coherus for toripalimab and the approval of the New Drug Application, we will provide a new treatment option for patients with nasopharyngeal cancer. Canada,” he said Allan ObermanPresident and CEO, Apotex. “The launch of toripalimab in Canada aligns with our strategic goal to continue to expand our innovative, branded pharmaceutical therapeutic areas as we pursue our vision of becoming a Canadian global healthcare company.”

Under the terms of the agreement, Apotex has the exclusive right to commercialize toripalimab in the market. Canada. Apotex will be responsible for obtaining marketing authorization for toripalimab in Canada and plans to seek approval of toripalimab as a treatment for patients with recurrent or metastatic nasopharyngeal carcinoma. Coherus will receive certain payments under the agreement, including an upfront payment and milestone payments upon achievement of certain regulatory and sales milestones.

About toripalimab

Toripalimab is an anti-PD-1 monoclonal antibody that blocks PD-L1 from binding to the PD-1 receptor at a unique high-affinity site and activates antitumor immunity. Toripalimab, approved in the U.S. as LOQTORZI^® (toripalimab-tpzi) is indicated in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC) and as a single agent for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after platinum-containing chemotherapy. For more information about LOQTORZI, including U.S. prescribing information and indications and important safety information, visit www.loqtorzi.com.

The story continues

About Apotex

Apotex is a Canadian global health company. We improve everyday access to affordable, innovative medicines and healthcare products for consumers around the world, with a broad portfolio of generic, biosimilar and innovative branded pharmaceutical products. Headquartered in Torontowith regional offices around the world, including United States, Mexico AND IndiaWe are Canada’s largest pharmaceutical company and the Americas’ premier healthcare partner for pharmaceutical licensing and product acquisition. Learn more about us at www.apotex.com.

SOURCE Apotex Inc.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/July2024/02/c9771.html